A panel of tests for hypercoagulability was performed and showed: protein S deficiency, presence of circulating lupus anticoagulant, heterozygous methylenetetrahydrofolate reductase (MTHFR) mutation and genotypes of plasminogen activator inhibitor (PAI), human platelet antigen (HPA), angiotensin converting enzyme (ACE), and apolipiprotein E (Apo E) with a moderate risk for thrombosis. The gene discussed is ACE; the disease is thrombophilia.